Schmidt, AF;
Pearce, LS;
Wilkins, JT;
Casas, JP;
Hingorani, AD;
(2018)
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
[Editorial comment].
Heart
, 104
(13)
pp. 1053-1055.
10.1136/heartjnl-2017-312858.
Preview |
Text
Casas Romero_Cochrane corner. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease_AAM.pdf - Accepted Version Download (177kB) | Preview |
Preview |
Text
Casas Romero_Cochrane corner. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease_Image.pdf - Accepted Version Download (8kB) | Preview |
Abstract
In this synopsis we describe findings from a recent Cochrane review on PCSK9 inhibitors for cardiovascular disease prevention. Compared against placebo, PCSK9 inhibitors show a substantial reduction in atherogenic lipid particles (LDL-C, Apo-B and Lp(a)), and protective effects on: CVD, MI, stroke, and elevated creatinine. There is however only limited, and lower quality, evidence comparing PCSK9 inhibitors against active treatments such as statins or ezetimibe. Furthermore, the current evidence is limited by the relatively short follow-up (at most a median follow-up of 26 months) which likely also relates to the observed beneficial safety profile, showing no clear signals on adverse events such as influenza, myalgia, T2DM or cancers.
Archive Staff Only
 |
View Item |
